Floatz logo

Niraparib

PALB2-Related Cancer Predisposition

Qian QinSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the PALB2-Related Cancer Predisposition cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University Health Network, Toronto
Phase 2/3B
TAMOXIFEN
European Institute of Oncology
Phase 2CCC
Dostarlimab
Dana-Farber Cancer Institute
Phase 2CCC
Abiraterone Acetate
Qian Qin
Phase 2CCC
Olaparib
Beth Israel Deaconess Medical Center
Phase 2CCC

View all 12 →

Same molecule, other indications

Niraparib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative ·
66 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →